Taro Pharmaceutical Industries - TARO Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $43.00
  • Forecasted Upside: 0.73%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$42.69
▼ -0.06 (-0.14%)

This chart shows the closing price for TARO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Taro Pharmaceutical Industries Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TARO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TARO

Analyst Price Target is $43.00
▲ +0.73% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Taro Pharmaceutical Industries in the last 3 months. The average price target is $43.00, with a high forecast of $43.00 and a low forecast of $43.00. The average price target represents a 0.73% upside from the last price of $42.69.

This chart shows the closing price for TARO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 1 polled investment analysts is to hold stock in Taro Pharmaceutical Industries. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/3/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/3/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/1/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/28/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/18/2024HC WainwrightDowngradeBuy ➝ Neutral$43.00Low
1/25/2023HC WainwrightLower TargetBuy$54.00 ➝ $35.00Low
8/15/2022HC WainwrightLower TargetBuy$73.00 ➝ $54.00Low
1/31/2022HC WainwrightLower TargetBuy$75.00 ➝ $73.00Medium
1/18/2022HC WainwrightLower TargetBuy$82.00 ➝ $75.00High
7/28/2021HC WainwrightBoost TargetBuy$80.00 ➝ $82.00High
6/2/2021HC WainwrightLower TargetBuy$81.00 ➝ $80.00Low
2/1/2021HC WainwrightBoost TargetBuy$80.00 ➝ $81.00Low
11/23/2020HC WainwrightLower TargetBuy$82.00 ➝ $80.00Medium
7/27/2020HC WainwrightLower TargetBuy$96.00 ➝ $82.00Low
6/19/2020HC WainwrightReiterated RatingBuy$96.00Low
5/21/2020HC WainwrightReiterated RatingBuy$94.00 ➝ $96.00High
2/4/2020HC WainwrightLower TargetBuy$110.00 ➝ $94.00Medium
11/5/2019HC WainwrightReiterated RatingBuy$105.00 ➝ $110.00High
8/12/2019HC WainwrightLower TargetBuy$115.00 ➝ $105.00Medium
(Data available from 5/27/2019 forward)

News Sentiment Rating

0.36 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/30/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/29/2023
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
12/29/2023
  • 4 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/28/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/27/2024
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/28/2024
  • 2 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
4/27/2024
  • 2 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/27/2024

Current Sentiment

  • 2 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Taro Pharmaceutical Industries logo
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprising allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic. The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution. It distributes and sells its products directly to wholesalers, retail drug chains, food chains, hospitals, mass merchandisers, e-commerce stores, and other direct consumers, as well as healthcare institutions and private pharmacies. The company was incorporated in 1959 and is based in Haifa, Israel. Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Alkaloida Chemical Company Zrt. As of June 30, 2023, Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Sun Pharmaceutical Industries Limited.
Read More

Today's Range

Now: $42.69
Low: $42.65
High: $42.76

50 Day Range

MA: $42.30
Low: $41.97
High: $42.78

52 Week Range

Now: $42.69
Low: $28.10
High: $45.76

Volume

45,900 shs

Average Volume

42,002 shs

Market Capitalization

$1.60 billion

P/E Ratio

29.65

Dividend Yield

N/A

Beta

0.6

Frequently Asked Questions

What sell-side analysts currently cover shares of Taro Pharmaceutical Industries?

The following Wall Street sell-side analysts have issued research reports on Taro Pharmaceutical Industries in the last year: HC Wainwright, StockNews.com, and TheStreet.
View the latest analyst ratings for TARO.

What is the current price target for Taro Pharmaceutical Industries?

1 Wall Street analysts have set twelve-month price targets for Taro Pharmaceutical Industries in the last year. Their average twelve-month price target is $43.00, suggesting a possible upside of 0.7%. HC Wainwright has the highest price target set, predicting TARO will reach $43.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $43.00 for Taro Pharmaceutical Industries in the next year.
View the latest price targets for TARO.

What is the current consensus analyst rating for Taro Pharmaceutical Industries?

Taro Pharmaceutical Industries currently has 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in TARO, but not buy more shares or sell existing shares.
View the latest ratings for TARO.

What other companies compete with Taro Pharmaceutical Industries?

How do I contact Taro Pharmaceutical Industries' investor relations team?

Taro Pharmaceutical Industries' physical mailing address is 14 HAKITOR ST PO BOX 10347, HAIFA BAY L3, 10532. The company's listed phone number is (724) 847-5700 and its investor relations email address is [email protected]. The official website for Taro Pharmaceutical Industries is www.taro.com. Learn More about contacing Taro Pharmaceutical Industries investor relations.